We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

24 hedge funds and large institutions have $28.3M invested in Palvella Therapeutics in 2016 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

0.59% more ownership

Funds ownership: 0% → 0.59% (+0.59%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

17% less funds holding

Funds holding: 29 → 24 (-5)

24% less capital invested

Capital invested by funds: $37.4M → $28.3M (-$9.14M)

63% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 8

Holders
24
Holders Change
-5
Holders Change %
-17.24%
% of All Funds
0.6%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
3
Increased
6
Reduced
3
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BI
BVF Inc
California
+$1.3M
2
Morgan Stanley
Morgan Stanley
New York
+$167K
3
Creative Planning
Creative Planning
Kansas
+$40.7K
4
RC
RBF Capital
California
+$38.7K
5
VKH
Virtu KCG Holdings
New York
+$22.3K

Top Sellers

1
LOAMU
Lombard Odier Asset Management (USA)
New York
-$1.15M
2
SM
Sabby Management
Florida
-$383K
3
OFM
Omega Fund Management
Massachusetts
-$235K
4
Renaissance Technologies
Renaissance Technologies
New York
-$79K
5
Deutsche Bank
Deutsche Bank
Germany
-$63K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$10.2M – – –
TCM
2
Tekla Capital Management
Massachusetts
$5.8M – – –
LOAMU
3
Lombard Odier Asset Management (USA)
New York
$3.4M -$1.15M -9,299 -23%
BI
4
BVF Inc
California
$2.61M +$1.3M +10,478 +82%
OFM
5
Omega Fund Management
Massachusetts
$2.38M -$235K -1,895 -8%
SM
6
Sabby Management
Florida
$1.81M -$383K -3,091 -16%
SFM
7
Sphera Funds Management
Israel
$1.13M – – –
DCM
8
DAFNA Capital Management
California
$314K – – –
Morgan Stanley
9
Morgan Stanley
New York
$256K +$167K +1,348 +145%
BFA
10
BlackRock Fund Advisors
California
$99K +$1.11K +9 +1%
Creative Planning
11
Creative Planning
Kansas
$65K +$40.7K +329 +132%
RC
12
RBF Capital
California
$45K +$38.7K +313 New
PAM
13
Panagora Asset Management
Massachusetts
$28K – – –
Bank of America
14
Bank of America
North Carolina
$25K – – –
OC
15
Oppenheimer & Co
New York
$23K +$2.23K +18 +10%
VKH
16
Virtu KCG Holdings
New York
$20K +$22.3K +180 New
Geode Capital Management
17
Geode Capital Management
Massachusetts
$18K – – –
BIT
18
BlackRock Institutional Trust
California
$17K – – –
LAM
19
Lebenthal Asset Management
New York
$14K – – –
UBS Group
20
UBS Group
Switzerland
$13K +$11.6K +94 +522%
AIM
21
Acrospire Investment Management
Illinois
$9K +$9.9K +80 New
BIM
22
BlackRock Investment Management
Delaware
$8K – – –
Manulife (Manufacturers Life Insurance)
23
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$4K – – –
Walleye Trading
24
Walleye Trading
New York
$3K – – –
Renaissance Technologies
25
Renaissance Technologies
New York
– -$79K -539 Closed
1
2

PVLA Hedge Fund Activity: Q4 2016 in Review

24 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q4 2016, worth a combined $28.3M — down 24% from $37.4M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of PVLA and 3 opened new positions — a net loss of 5 holders — while 3 trimmed existing stakes and 6 added.

The largest buyer was BVF Inc, adding an estimated $1.3M. The largest seller was Lombard Odier Asset Management (USA), cutting an estimated $1.15M.

  • 24 institutional investors held Palvella Therapeutics (PVLA) as of Q4 2016, down from 29 in Q3 2016.
  • Funds reported $28.3M of Palvella Therapeutics stock for Q4 2016, down 24% quarter-over-quarter.
  • 3 funds opened new Palvella Therapeutics positions in Q4 2016 and 8 closed out, a net change of -5 holders.
  • The largest Palvella Therapeutics buyer in Q4 2016 was BVF Inc, an estimated $1.3M added.
  • The largest Palvella Therapeutics seller in Q4 2016 was Lombard Odier Asset Management (USA), an estimated $1.15M sold.

Based on aggregated 13F filings for Q4 2016.